OCTIMET oncology was founded in 2016 by Timothy Perera PhD, Ann Meulemans PhD, Paolo Comoglio, MD, PhD and Philip Owen.
Headed by Dr. Timothy Perera (CEO), OCTIMET has licensed highly selective MET kinase inhibitors with clean safety profiles from Janssen Pharmaceutica and will advance the development of these molecules by employing innovative patient selection and pharmacodynamic biomarker-based strategies, as well as an innovative clinical development strategy, to provide differentiation both within the current treatment paradigms and from competitor agents using biomarker defined intelligent patient selection.
The MET oncogene activated signalling pathway is known to be hyper-activated in identifiable subsets of a range of major cancer types. The MET receptor has recently been demonstrated to be a functional marker of cancer stem like cells that are responsible for the development of resistance to radiotherapy and a number of chemotherapy and targeted anti-cancer agents. Inhibition of the MET kinase signalling pathway has been demonstrated to block MET driven cancers and overcome MET induced resistance to a range of therapeutic agents leading, in some cases, to the cure of tumor bearing preclinical animals. OCTIMET have proprietary knowledge of pathways and targets that would result in rational combination therapeutic partners.
OMO-1 is a highly selective small molecule MET kinase inhibitor that has demonstrable single agent cellular and in vivo activity only in MET driven preclinical models as expected from a highly selective agent. OMO-1 has recently been explored in a healthy volunteer trial where predicted efficacious exposures were reached without any significant adverse events. Available dose and exposure correlations and optimal dosing regimes that were defined in this healthy volunteer trial will guide and expedite clinical evaluation in forthcoming patient trials.
The clean safety profile observed in the healthy volunteer trial needs to be confirmed in an accelerated Phase 1 dose escalation study carried out in non selected cancer patients followed by demonstrating evidence of clinical activity in a MET biomarker selected expansion cohort.
A Phase 2a study to confirm activity in MET biomarker selected population will generate proof of concept data to support a larger registration trial.
Innovative study design and timelines that are envisaged will allow OMO-1 to leapfrog competitors and achieve best in class status. Based on the high combination potential inherent to OMO-1 and known MET pharmacology, additional opportunities for significantly increasing market size exist in a range of indications with a defined set of evidence driven, biomarker selected, combination partners.
OMO-2 is a differentiated follow-up MET-inhibitor with similar high selectivity that is in late non-clinical development.
Images courtesy of Letizia Lanzetti - Membrane Trafficking Laboratory - Candiolo Cancer Institute- FPO, IRCCS - Torino (Italy)
Beerse, Belgium January 19th 2017: OCTIMET Oncology NV (OCTIMET), has secured EUR 11.3 million in a Series A investment round, enabling the company to accelerate the clinical development of clinically de-risked MET kinase inhibitors, as single agent or in combination with standard of care and targeted agents for the treatment of solid cancers.
OCTIMET was founded in 2016 by Timothy Perera PhD, Ann Meulemans PhD, Paolo Comoglio, MD, PhD and Philip Owen FCA. Headed by Dr. Timothy Perera, OCTIMET has licensed from Janssen Pharmaceutica, highly selective MET kinase inhibitors with clean safety profiles and will advance the development of these molecules by employing innovative patient selection and pharmacodynamic biomarker-based approaches, as well as an innovative clinical development strategy, to provide differentiation both within the current treatment paradigms and from competitor agents.